CD47 and non-Hodgkin lymphoma: Taking into account the promising results obtained by combining anti-CD47 therapy with rituximab in NHL (discussed earlier), we consider the clinical trial testing if the combination of anti-CD47 therapy (such as Magrolimab) plus antiangiogenic therapy should begin in the foreseeable future and could provide a new therapeutic alternative for patients with NSCLC.